Version 1
: Received: 5 June 2020 / Approved: 7 June 2020 / Online: 7 June 2020 (16:21:35 CEST)
Version 2
: Received: 16 August 2020 / Approved: 20 August 2020 / Online: 20 August 2020 (09:06:38 CEST)
How to cite:
Nejat, R.; Sadr, A.S.; Ebrahimi, A.; Nabati, A.; Eshaghi, E. Daily Low Dose of Erythropoietin and Neuroinflammation. Preprints2020, 2020060107. https://doi.org/10.20944/preprints202006.0107.v1
Nejat, R.; Sadr, A.S.; Ebrahimi, A.; Nabati, A.; Eshaghi, E. Daily Low Dose of Erythropoietin and Neuroinflammation. Preprints 2020, 2020060107. https://doi.org/10.20944/preprints202006.0107.v1
Nejat, R.; Sadr, A.S.; Ebrahimi, A.; Nabati, A.; Eshaghi, E. Daily Low Dose of Erythropoietin and Neuroinflammation. Preprints2020, 2020060107. https://doi.org/10.20944/preprints202006.0107.v1
APA Style
Nejat, R., Sadr, A.S., Ebrahimi, A., Nabati, A., & Eshaghi, E. (2020). Daily Low Dose of Erythropoietin and Neuroinflammation. Preprints. https://doi.org/10.20944/preprints202006.0107.v1
Chicago/Turabian Style
Nejat, R., Alireza Nabati and Elham Eshaghi. 2020 "Daily Low Dose of Erythropoietin and Neuroinflammation" Preprints. https://doi.org/10.20944/preprints202006.0107.v1
Abstract
Neuroinflammation, defined as inflammatory reactions mediated by cytokines, chemokines, reactive oxygen species, and secondary messengers in the central nervous system (CNS) including the brain and spinal cord is the basis of many neurological disorders [1] Recently, erythropoietin (EPO) has been considered and studied as a modulator of neuroinflammation.[2-4]On this article minireview of pathophysiology of neuroinflammation and the neuroprotective effects of EPO is discussed and a case of subacute huge subdural hematoma with double mydriasis operated urgently, treated with low daily dose (vs high dose once or twice a month in the literature) of EPO and recovered fully and discharged home with good consciousness is reported. In addition, the probable outcome of erythropoietin administration in patients with neuroinflammation in COVID19 is considered.
Keywords
Ang II; COVID19; erythropoietin; EPO-R
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
